Direct Health Care Costs Associated with Asthma Hospitalizations Before and

During the Covid-19 Pandemic in the United States: A Nationwide Inpatient

Sample Analysis.

*N. Solanki², *B. F. Fakhry¹, P. Zhang², A. Attaway², J. Zein³, W. Tsuang²

¹Inflammation and Immunity, Lerner Research Institute Cleveland Clinic, Cleveland, OH,

United States.

²Pulmonary/Critical Care, Cleveland Clinic, Cleveland, OH, United States.

³Pulmonary and Critical Care Medicine, Mayo Clinic, Scottsdale, AZ, United States

*: contributed equally to the manuscript

Running Title: Effect of Covid-19 Pandemic on Asthma Hospitalizations

CORRESPONDENCE TO:

Neha Solanki, MD

Address: 9500 Euclid Avenue, Cleveland, OH 44195

Email: solankn@ccf.org

Acknowledgements: Dr. Serpil Erzurum

Funding/support: Cleveland Clinic Research Program Committee Grant

Financial/nonfinancial disclosures: None declared.

Key words: epidemiology, asthma, covid-19, pandemic, nationwide inpatient sample analysis.

Author Contributions:

Neha Solanki: Conceptualization, methodology, software, formal analysis, writingreview and editing, project administration; **Battoul Fakhry:** methodology, software,

formal analysis, investigation, data curation, writing-original draft; **Peng Zhang:** formal analysis, writing-review and editing; **Amy Attaway:** formal analysis, writing-review and editing; **Joe Zein:** resources, writing- review and editing ; **Wayne Tsuang:** writing-review and editing, visualization, supervision

Abstract word count: 234

Manuscript word count: 3497

Conflict of Interest: The authors have no relevant conflicts of interest to disclose.

Ethics: Our paper does not require ethical approval. The data from NIS are de-

identified, thus exempting review

Abstract

Background: Asthma, a chronic inflammatory airway disorder, can increase the risk of hospitalizations in individuals with viral infections such as COVID-19. The impact of the COVID-19 pandemic on asthma-related hospitalizations in the United States remains unknown.

Objective: We hypothesized that the COVID-19 pandemic led to an increase in economic burden to society and a decrease in hospitalization rates for asthma. Methods: We analyzed weighted data from National Inpatient Sample (NIS) between January 1, 2018, and December 31, 2020. The outcomes were asthma hospitalization rates, length of stay (LOS), in-hospital mortality rates, and hospital admission costs. **Results:** More people were admitted with a primary diagnosis of asthma in 2018 and 2019 compared to 2020 (hospitalization rate per 100,000: 2018: 38.6 versus (vs) 2019:37.0 vs 2020: 21.4 ; P < 0.001). Hospital costs increased (2018: median [IQR] 5,251 [3,426, 8,278]; 2019:5,677 [3,725, 8.969]; 2020: 5,881 [3,920-9,216]; P <0.001). Additionally, in-patient mortality rates slightly increased in 2020, rising to 0.44%, compared to 0.20% in 2018 and 0.30% in 2019 (P < 0.001). When comparing geographic divisions, the mid-Atlantic division had the highest hospitalization rates, and the Pacific division had the highest hospitalization costs from 2018-2020 (P < 0.05). **Conclusion:** Asthma hospitalizations decreased in 2020 compared to previous years. Those admitted during the pandemic had slightly higher mortality and significantly

increased hospital costs. This investigation provides valuable insights for policy makers about shifts in healthcare utilization during the pandemic.

Abbreviations:

AHRQ	Agency for Healthcare Research and Quality
APR-DRG	All Patient Refined Diagnosis Related Group
CCR	Cost-To-Charge Ratios
COPD	Chronic Obstructive Pulmonary Disease
ED	Emergency Department
HCUP	Healthcare Cost and Utilization Project
NIS	National Inpatient Sample
US	United States
USD	United States Dollars

Introduction

Asthma is a chronic airway disease marked by variable airflow limitation and airway inflammation¹. The impact of asthma is large in the United States (US), affecting approximately 25 million individuals and placing a substantial burden on healthcare utilization². In 2019, uncontrolled asthma resulted in nearly 1.8 million emergency department (ED) visits,169,330 hospitalizations, and 4.9 million clinic visits in the US^{3,4}. Asthma places a considerable economic burden on patients and society with an estimated cost of more than \$80 billion between 2008 and 2013 ⁵.

The COVID-19 pandemic disrupted the US healthcare system with widespread social distancing measures. These restrictions resulted in the cancellation of clinics and procedures, thereby reducing patient access to healthcare services⁶. Simultaneously, hospitals faced challenges in managing the influx of acutely ill patients with COVID-19⁷. Despite the high prevalence of COVID-19 infections, both hospitalizations and ED visits for acute asthma cases decreased in several countries^{8–12}. According to the National Syndromic Surveillance Program, EDs in the US had a 31% relative decrease in weekly visits for pediatric asthma in 2020 compared to 2019¹³. The United Kingdom demonstrated a similar decrease in visits to the ED for asthma and a decline in hospital admissions from 2019 to 2020^{12,14}.

It remains unclear how the pandemic influenced healthcare access, costs, and outcomes for asthma patients. Existing studies primarily focus on the decrease in ED visits and hospital admissions, but they do not comprehensively address the economic impact or changes in healthcare utilization patterns^{7,1510,16,17}. We utilized the National Inpatient Sample (NIS) Database, the largest publicly available all-payer inpatient

healthcare database, to investigate regional and national estimates of inpatient utilization, access, cost, and outcomes. We hypothesized that the COVID-19 pandemic was associated with a decrease in hospital admissions for patients with asthma along with an increase in hospitalization costs because of longer hospital stays.

Methods

Data source

We used the Healthcare Cost and Utilization Project (HCUP)-National Inpatient Sample (NIS) for the years 2018-2020. NIS captures more than 95% of US hospital admissions with nearly 8 million hospitalizations annually. NIS represents a wide array of hospitals sampled to reflect about one-fifth of US community hospitals^{18,19}.

Study design and population

We queried the NIS database between January 1st, 2018, to December 31st, 2020, using the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM). Patients with a primary diagnosis of asthma (ICD-10-CM code: J45.XX) were included in the study (n = 88,484 patients) (Figure E1). Participants with missing data were excluded.

We performed analysis on patients admitted in 2020 with a primary diagnosis of COVID-19 (ICD-10 codes U07.9, J12.89, B97.29) and a secondary diagnosis of asthma.

The data from NIS are de-identified, thus exempting review by the Institutional Review Board of the Cleveland Clinic.

Time frame definitions

We organized our data into strata based on years and quarters with Q1 representing January to March, Q2 for April to June, Q3 for July to September, and Q4 for October to December (Figure E2). We defined the period spanning from January 1, 2018, to December 31, 2019 as the pre-COVID-19 era. The timeframe from January 1, 2020 to December 31, 2020 represented the early COVID-19 era.

Outcome measures and variables

The primary outcome was hospital admission cost. The secondary outcome variables included asthma hospitalization rate, length of stay (LOS), and in-hospital mortality rate. The HCUP's NIS provides data on total charges for each hospital, reflecting the billed amount for all services rendered. Cost was adjusted for inflation according to consumer price index (CPU) for medical services in December 2020 (Appendix 1)²⁰. The LOS was estimated in days after excluding those who died in the hospital. We categorized LOS into two groups LOS > 7 days and LOS <7 days.

We compared outcomes between pre-COVID-19 and the early COVID-19 periods. In addition, we examined disparities in outcomes across age groups, sex, race, household income, and insurance type (Table E1, E2 and Appendix 1-3). Outcome variables were stratified based on geographic division determined by the US Census Bureau²¹. The states representing each of the nine Census Divisions are shown in Figure E3.

Statistical analysis

To generate national estimates, we used analytic sample weights (dischargelevel weight: DISCWT) for patient level observations as described by HCUP guidelines ²². We represented categorical variable as percentages, and unadjusted comparisons between groups and were performed using Chi-squared test. Continuous and nonsymmetrical variables were represented as medians [interquartile range], and differences were tested using the Mann–Whitney U test/Wilcoxon rank-sum test.

We conducted weighted regression analysis. Multivariate logistic regression was used for categorical outcomes (in-patient mortality, LOS> 7days), and presented as adjusted odds ratios with 95% confidence intervals (CI) (Appendix 3). In all multivariate models, we included all parameters described in Table E1 and tested for multicollinearity. All tests were two-tailed, and the level of statistical significance was set at P <0.05. All analyses were performed using JMP software (Cary, NC, USA).

Results

Annual Cost of Asthma Hospitalizations

Overall median asthma hospitalization cost was 5,552 [3,635, 8,751] USD. It rose from 5,251 [3,426, 8,278] USD in 2018 to 5,881 [3,920, 9,216] USD in 2020 (Table 1, Figure E4). The second quarter of 2020 had the lowest cost related to asthma hospitalization during the pandemic (Figure 1).

The cost of an asthma admission surged across all geographic divisions in 2020 compared to the pre-pandemic period (P<0.05). Notably, the Pacific division had the highest hospitalization costs compared to other divisions annually between 2018 and 2020 (P<0.05) (Figure 2). Over the span of three years, there was a notable increase in hospitalization costs within this division (P=0.004), which was particularly evident when comparing 2020 to 2018 (P=0.005), although the increase between 2019 and 2020 did not reach statistical significance.

Using a multivariable linear regression model adjusted for patients' demographic characteristics, socioeconomic status, and chronic medical comorbidities, we found the

cost of asthma admission in 2020 was 6.2% higher than pre-pandemic period, corresponding to an adjusted exponential of the slope for cost (95% CI) of 1.03 (1.03-1.04) (Table 2). Figure E2 provides a more detailed stratification of yearly asthma hospitalization cost by quarter.

Annual trends in asthma hospitalizations

Overall, 63,740 weighted asthma admissions were recorded between 2018 and 2020 (Table 1). The rate of asthma hospitalization decreased from 38.6 per 100,000 in 2018 to 21.4 per 100,000 in 2020 (P <0.0001), with the most notable decline between April and June (Figure 1-B, E*5*).

The overall median age of patients admitted for asthma was 38 [14,56] years. There was a significant increase in admissions among patients aged 20-44 and 45-64 years (P<0.0001) over the 3 years. Females demonstrated a modest but significant rise in hospitalizations from 63.1% in 2018 to 64.5% in 2020 (P<0.0001). Additionally, there was an increasing trend in asthma admissions for White and Black patients, while hospitalizations for Hispanic patients decreased (Table 1).

Comorbidities such as obesity (24.5% in 2018 to 28.3% in 2020), cardiovascular diseases (13.6% in 2018 to 15.7% in 2020), and anxiety (15.0% in 2018 to 18.3% in 2020) saw slight increases, while substance abuse rose notably in 2020 (7.1% in 2018 to 9.7% in 2020) (P < 0.0001) (Table 1).

The All Patient Refined Diagnosis Related Groups (APRDRG) are a clinical model that classifies patients based on their severity of illness, risk of mortality and reason for admission. The APRDRG of illness showed a slight increase in cases classified as major (21.87% in 2020) and extreme (5.76% in 2020). The risk of mortality

categories reflected higher severity, with extreme likelihood of mortality rising to 3.35% in 2020 from 2.39% in 2019 and 1.94% in 2018. Most patients were discharged routinely (89.8% in 2020), with slight increases in home health care transfers (5.1%) and discharges against medical advice (3.9%) in 2020 (Table 1).

Asthma hospitalization rates decreased in all divisions in 2020 compared to prepandemic levels (P <0.0001) (Figure 3). The Mid-Atlantic division consistently had the highest hospitalization rates each year (P <0.001). This division experienced a significant reduction in hospitalizations over the three years (P<0.01), with marked decreases in 2020 compared to both 2018 (P <0.04) and 2019 (P<0.04).

Further stratification of annual asthma hospitalization characteristics by quarter are detailed in figure E6 and E7.

Annual trends in hospital mortality

In-patient mortality rates modestly increased in 2020 (0.44%) compared to 2019 (0.30%) and 2018 (0.20%) (Table 1). During the pandemic, Q3 had the lowest mortality rate (Figure 1-C). In 2018, the East North Central division had the highest mortality rate among all divisions (P<0.05), whereas in 2019, the Mountain division recorded the highest rate (P<0.05). During the pandemic, the Mid-Atlantic division experienced the highest mortality rate compared to other divisions (P<0.05) (Figure 4).

Using a multivariable linear regression model adjusted for patients' demographic characteristics, socioeconomic status, and chronic medical comorbidities, our analysis revealed odds of in-patient mortality were 27% higher during the COVID-19 pandemic than in the pre-pandemic period (aOR (95% CI): 1.27 (1.10-1.50)) (Table 2).

Figure E9 provides a more detailed stratification of yearly in-patient mortality by quarter.

Annual trends in length of stay

The overall median LOS was 2 [1,3] days, which remained consistent across the 3 years and the percentage of patients with a LOS >7 days remained stable at 6.0% (Table 1). Q2 had the lowest proportion of patients with LOS >7 days (Figure 1, Figure E8). During early pandemic, admission with LOS >7 days decreased in all divisions compared to pre-pandemic levels, except for the Mid-Atlantic, East North Central, and Mountain divisions. The Mid-Atlantic division consistently had the highest rate of hospitalizations with LOS >7 days compared to other divisions in every year (p <0.05) (Figure 5).

Using a multivariable linear regression model adjusted for patients' demographic characteristics, socioeconomic status, and chronic medical comorbidities, we found that patients with asthma were more likely to have a shorter admission (exponential of slope for LOS (95% CI) during the COVID-19 period: 0.99 (0.98-0.99)). In addition, the odds of asthma admission of more than 7 days were 5% lower during COVID-19 pandemic than in the pre-pandemic period (aOR (95% CI): 0.95 (0.91-0.98)) (Table 2).

Figure E9 provides a more detailed stratification of yearly LOS by quarter. COVID-19 hospitalizations with secondary diagnosis of asthma

To differentiate healthcare utilization patterns between COVID-19 and asthma admissions, we conducted a secondary analysis on the NIS cohort of 1,079,310 individuals with a primary diagnosis of COVID-19 and a secondary diagnosis of asthma. The admission rate reached 325.6 per 100,000. We found that 508,910 (47%) of the

patients were female, with a median age of 66 years [53,77]. Additionally, 547,295 (50%) were admitted during the last quarter of the year, with a median length of stay (LOS) of 5 days [3,9]. The South Atlantic division had the highest admission rate compared to other geographic divisions, accounting for 218,890 (20%) of the total admissions (Figure E10).

Discussion

Main findings

The start of the COVID-19 pandemic was marked by a shift in healthcare utilization and economic burden. Using the NIS-HCUP dataset, we found that the median cost of asthma hospitalizations rose from \$5,251 in 2018 to \$5,881 in 2020, with significant geographic disparities, particularly in the Pacific division. Despite the rising costs, the rate of asthma hospitalizations significantly dropped from 38.6 per 100,000 in 2018 to 21.4 per 100,000 in 2020. The demographics of admitted patients revealed an increase in severity and comorbidities, such as obesity and cardiovascular diseases, while in-patient mortality rates modestly increased during the pandemic. However, the length of stay remained stable. In comparison, COVID-19 hospitalizations with a secondary diagnosis of asthma indicated significant healthcare utilization, with the South Atlantic region having the highest admission rates. Though the rate of hospitalizations for asthma as a primary diagnosis to COVID-19 increased.

Cost of asthma hospitalizations

According to an analysis of the Medical Expenditure Panel Survey asthma imposes a significant and increasing economic burden on the US⁵, with an estimated

\$960 billion in direct and indirect costs projected between 2019 and 2038²⁵. In 2013, the annual per-person cost of hospitalization was \$529⁵. In 2020, the COVID-19 pandemic aggravated this burden, with a notable increase in admission costs by more than \$700 from 2018, resulting in a median cost of \$5,881. We noted a 6.2% rise in asthma hospitalization costs which is higher than the general inflation rate for medical services of 2.8% in 2020²⁰. We speculate that this increase in asthma admission costs could be attributed to several reasons, including loss of revenue by US hospitals. The American Hospital Association revealed that US hospitals experienced a total loss of over \$200 billion between March 1 and June 30, 2020. This was primarily due to an estimated 45% decrease in operating revenue driven by a reduction in elective procedures and routine care as hospitals focused on treating COVID-19 patients²⁶. Second, during the pandemic there has been an increase in operating expenses, driven by shortages and unprecedented inflation that escalated the costs of medical supplies, drugs, and equipment^{20,27,28}. It was estimated that drug expenses increased by 36.9% and medical supplies by 0.6% from pre-pandemic period²⁷. Third, a significant workforce shortage has emerged as caregivers have been affected by COVID-19, forcing hospitals to rely heavily on more expensive contract labor and increase hazard pay^{27,28}. Fourth, there has been an increase in patient acuity as the result of delaying or deferring care caused by fears of related to COVID-19^{29,3029,31}. We found that admitted patients showed higher degrees of loss of function due to asthma, had more comorbidities, and experienced prolonged lengths of stay. Consequently, this resulted in higher healthcare expenditures and increased costs.

We found that highest hospitalization costs were in the Pacific division of the US. This variation in hospitalization costs across different regions of the US aligns with findings from previous studies³² which showed regional disparities in healthcare expenses. This could be attributed to differences in local healthcare policies, the cost of living, patient population characteristics, and hospital operational expenses.

Healthcare Utilization patterns

The early phase of the COVID-19 pandemic saw a significant decrease in asthma admissions^{8,11,15} compared to pre-pandemic levels. The most pronounced decrease in asthma admissions occurred between April and June 2020, coinciding with the initial phases of the COVID-19 pandemic when lockdowns and preventative measures were most stringent. This decline in asthma admissions could be due to several factors. Lockdown measures reduced exposure to common asthma triggers such as outdoor pollutants and respiratory infections, possibly leading to fewer exacerbations³³. Behavioral changes included adherence to medications and preventive measures such as wearing masks and social distancing^{16,34,35}. Additionally, concerns about contracting COVID-19 in healthcare settings discouraged asthma patients from seeking emergency care unless absolutely necessary³⁶. The observed decline in asthma admissions during COVID-19 underscores the impact of public health measures and patient behavior on disease outcomes.

Despite a national decline in asthma hospitalization rates between 2018 and 2020, the Mid-Atlantic division, which includes New York, New Jersey, and Pennsylvania, had higher rates of asthma admissions. Although air quality improved

during lockdowns³³, individuals with asthma in the Mid-Atlantic might have been more exposed to poor indoor air quality, or to indoor allergens such as dust mites, mold, pet dander³⁹. Another possible reason could be disparities in access to care, which could lead to higher hospitalization rates³⁹.

In-patient mortality during asthma hospitalization

We observed an increase in mortality rate, with a 27% higher likelihood of death during the pandemic compared to the pre-pandemic period^{40,41}. The sudden surge in COVID-19 cases overwhelmed healthcare facilities^{7,41}. Many individuals requiring routine medical attention experienced cancellations and delays in receiving treatment³⁰. These disruptions increased the likelihood of disease progression, elevating the risk of severe illness and mortality among non-COVID-19 patients⁴¹. Moreover, patients admitted to hospitals were often older and from lower socio-economic backgrounds⁴⁰. Many patients had pre-existing chronic conditions, which compounded their vulnerability⁴⁰. The convergence of these factors led to an increase in patient mortality as the healthcare system struggled to provide adequate care amidst the unprecedented demand⁴¹. The Mid-Atlantic division recorded the highest mortality rate compared to other divisions.

Length of stay (LOS) of asthma hospitalizations

The LOS remained consistent across the three years with a 5% reduced likelihood of being admitted for more than 7 days. This finding differs from that reported by McAlister et al., where patients hospitalized with non-COVID-19 conditions had a mean LOS of 9 days both before and during the pandemic⁴². Another study reported a longer hospital stay among non-COVID-19 patients during the same period³¹. A reason for this discrepancy could be variations in healthcare system capacity, patient demographics, or local pandemic management strategies that influenced hospital workflows and resource availability. Those factors could account for the observed geographic division disparities in LOS in our study. The lowest proportion of patients with prolonged LOS was reported in Q2. The surge of COVID-19 cases in Q2 in March 2020 led to hospitals reaching or exceeding capacity. Hospitals allocated nearly all their resources to treating COVID-19 patients, leaving a little room for non-COVID-19 cases such as asthma³⁰.

COVID-19 vs. asthma admissions during the pandemic

When compared to asthma admissions, the rate of hospitalization for COVID-19 with a secondary asthma diagnosis was 15 times higher. In contrast to the demographics of asthma hospitalizations, males with chronic asthma were more frequently admitted for COVID-19, consistent with existing literature. In addition, patients with COVID-19 were older and stayed longer in the hospital due to more severe disease in the setting of their chronic airway inflammation and underlying comorbidities^{44,45}. Furthermore, we observed the highest rate of COVID-19 in individuals with asthma in the South Atlantic division.

During the early pandemic period, healthcare utilization patterns differed between patients with asthma hospitalized for COVID-19 and those admitted solely for asthma as COVID-19 admissions required greater healthcare resources.

Limitations

A major limitation of this study is the use of asthma as a primary diagnosis. Over one million individuals were admitted to the hospital with COVID-19 as a primary diagnosis and asthma as a secondary diagnosis in 2020, thus most individuals with respiratory conditions were more likely to have COVID-19 as a primary diagnosis and asthma as a secondary diagnosis. Therefore, the contribution of asthma to the hospitalizations, mortality, and length of stay in our study is likely underestimated. A second limitation is its observational approach, thus we are unable to establish causal effect. Despite these limitations, the HCUP-NIS data offers many advantages in asthma research in that it is a large nationally representative sample drawn from patient health records.

Conclusion

We found that the COVID-19 pandemic was associated with decreased asthma hospitalizations and increased healthcare costs. The social distancing protocols and policies during the pandemic may have reduced asthma exacerbations requiring admission. However, avoidance of the healthcare system may have increased asthma severity and healthcare cost for those who were admitted. Our findings suggest that pandemic mitigation strategies are needed to educate patients with asthma on when to seek medical care to avoid adverse outcomes.

References:

- 1. Merhej T, Zein JG. Epidemiology of Asthma: Prevalence and Burden of Disease. In: Brasier AR, Jarjour NN (eds) *Precision Approaches to Heterogeneity in Asthma*. Cham: Springer International Publishing, pp. 3–23.
- Centers for Disease Control and Prevention. Most Recent National Asthma Data. 2023 [Accessed March 13th,2024]. Available from: https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm.
- Centers for Disease Control and Prevention. 2020 Archived Most Recent National Asthma Data. 2023 [Accessed March 13th,2024]. Available from:https://www.cdc.gov/asthma/archivedata/2020/2020_archived_national_data.ht ml.
- 4. National Center For Health Statistics. National Ambulatory Medical Care Survey:2019 National Summary Tables. 2023 [Accessed June 4th,2024]. Available from:https://www.cdc.gov/nchs/data/ahcd/namcs_summary/2019-namcs-web-tables-508.pdf.
- 5. Nurmagambetov T, Kuwahara R, Garbe P. The Economic Burden of Asthma in the United States, 2008–2013. *Ann Am Thorac Soc* 2018; 15: 348–356.
- 2023 National Healthcare Quality and Disparities Report. Rockville (MD): Agency for Healthcare Research and Quality (US), http://www.ncbi.nlm.nih.gov/books/NBK600459/ (2023, accessed 24 June 2024).
- 7. Huggins A, Husaini M, Wang F, et al. Care Disruption During COVID-19: a National Survey of Hospital Leaders. *J Gen Intern Med* 2023; 38: 1232–1238.
- 8. Galán-Negrillo M, García-Pachón E. Reduction in Hospital Admissions for Asthma and COPD During the First Year of COVID-19 Pandemic in Spain. *Arch Bronconeumol* 2023; 59: 537–539.
- 9. Abe K, Miyawaki A, Nakamura M, et al. Trends in hospitalizations for asthma during the COVID-19 outbreak in Japan. *J Allergy Clin Immunol Pract* 2021; 9: 494-496.e1.
- 10. De Boer G, Braunstahl G-J, Hendriks R, et al. Asthma exacerbation prevalence during the COVID-19 lockdown in a moderate-severe asthma cohort. *BMJ Open Respir Res* 2021; 8: e000758.
- Birkmeyer JD, Barnato A, Birkmeyer N, et al. The Impact Of The COVID-19 Pandemic On Hospital Admissions In The United States. *Health Aff (Millwood)* 2020; 39: 2010–2017.
- 12. Davies GA, Alsallakh MA, Sivakumaran S, et al. Impact of COVID-19 lockdown on emergency asthma admissions and deaths: national interrupted time series analyses for Scotland and Wales. *Thorax* 2021; 76: 867–873.

- 13. Ye D, Gates A, Radhakrishnan L, et al. Changes in asthma emergency department visits in the United States during the COVID-19 pandemic. *J Asthma* 2023; 60: 1601–1607.
- 14. Shah SA, Quint JK, Sheikh A. Impact of COVID-19 pandemic on asthma exacerbations: Retrospective cohort study of over 500,000 patients in a national English primary care database. *Lancet Reg Health Eur* 2022; 19: 100428.
- 15. Lam RW, Inselman JW, Jeffery MM, et al. National decline in asthma exacerbations in United States during coronavirus disease 2019 pandemic. *Ann Allergy Asthma Immunol* 2021; 127: 692–694.
- 16. Moore WC, Ledford DK, Carstens DD, et al. Impact of the COVID-19 Pandemic on Incidence of Asthma Exacerbations and Hospitalizations in US Subspecialist-Treated Patients with Severe Asthma: Results from the CHRONICLE Study. *J Asthma Allergy* 2022; Volume 15: 1195–1203.
- 17. Khan NS, Rubin E, McKenna B, et al. The COVID-19 impact on severe uncontrolled asthma costs and biologic use. *Allergy Asthma Proc* 2023; 44: 340–344.
- Healthcare Cost and Utilization Project: Overview of the National (Nationwide) Inpatient Sample (NIS).2024 [Accessed March 6th, 2024]. Available from: https://hcup-us.ahrq.gov/nisoverview.jsp.
- 19. Meier SK, Pollock BD, Kurtz SM, et al. State and Government Administrative Databases: Medicare, National Inpatient Sample (NIS), and State Inpatient Databases (SID) Programs. *J Bone Jt Surg* 2022; 104: 4–8.
- 20. U.S. Bureau of Labor Statistics. 12-month percentage change, Consumer Price Index, selected categories. Accessed March 10th, 2024. Available from: https://www.bls.gov/charts/consumer-price-index/consumer-price-index-by-category-line-chart.htm.
- Census Bureau Regions and Divisions with State FIPS Codes. Accessed March 6, 2024. Available from: https://www2.census.gov/geo/docs/mapsdata/maps/reg_div.txt.
- 22. Producing National HCUP Estimates. Accessed March 15, 2024. Available from: https://hcupus.ahrq.gov/tech_assist/nationalestimates/508_course/508course_2018.jsp.
- 23. Lakens D. Equivalence Tests: A Practical Primer for *t* Tests, Correlations, and Meta-Analyses. *Soc Psychol Personal Sci* 2017; 8: 355–362.
- 24. Qiu L, Kumar S, Sen A, et al. Impact of the Hospital Readmission Reduction Program on hospital readmission and mortality: An economic analysis. *Prod Oper Manag* 2022; 31: 2341–2360.

- 25. Yaghoubi M, Adibi A, Safari A, et al. The Projected Economic and Health Burden of Uncontrolled Asthma in the United States. Am J Respir Crit Care Med 2019; 200: 1102–1112.
- 26. American Hospital Association. Hospitals and Health Systems Continue to Face Unprecedented Financial Challenges Due to COVID-19. May 2020. [Accessed June 27th, 2024]. Available from:https://www.aha.org/system/files/media/file/2020/05/aha-covid19-financial-impact-0520-FINAL.pdf.
- American Hospital Association. Massive Growth in Expenses and Rising Inflation Fuel Continued Financial Challenges for America's Hospitals and Health Systems. April 2022. [Accessed June 27th, 2024]. Available from: https://www.aha.org/system/files/media/file/2022/04/2022-Hospital-Expenses-Increase-Report-Final-Final.pdf.
- American Hospital Association. The Financial Stability of America's Hospitals and Health Systems Is at Risk as the Costs of Caring Continue to Rise. April 2023 [Accessed June 27th, 2024]. Available from: https://www.aha.org/system/files/media/file/2023/04/Cost-of-Caring-2023-The-Financial-Stability-of-Americas-Hospitals-and-Health-Systems-Is-at-Risk.pdf.
- American Hospital Association. Pandemic-Driven Deferred Care Has Led to Increased Patient Acuity in America's Hospitals. August 2022. [Accessed March 13th,2024]. Available from: https://www.aha.org/system/files/media/file/2022/08/pandemic-driven-deferred-carehas-led-to-increased-patient-acuity-in-americas-hospitals.pdf.
- 30. Ponce SA, Wilkerson M, Le R, et al. Inability to get needed health care during the COVID-19 pandemic among a nationally representative, diverse population of U.S. adults with and without chronic conditions. BMC Public Health 2023; 23: 1868.
- 31. Gasch-Illescas A, Calle-Serrano M, Vallejo-Vaz AJ, et al. Impact of the first wave of the COVID-19 pandemic on non-COVID inpatient care in southern Spain. Sci Rep 2023; 13: 1634.
- 32. Nurmagambetov T, Khavjou O, Murphy L, et al. State-level medical and absenteeism cost of asthma in the United States. J Asthma 2017; 54: 357–370.
- 33. Jevtic M, Matkovic V, Van Den Hazel P, et al. Environment—lockdown, air pollution and related diseases: could we learn something and make it last? Eur J Public Health 2021; 31: iv36–iv39.
- 34. Polivka BJ, Eldeirawi K, Huntington-Moskos L, et al. Mask Use Experiences, COVID-19, and Adults with Asthma: A Mixed-Methods Approach. J Allergy Clin Immunol Pract 2022; 10: 116–123.

- 35. Kaye L, Theye B, Smeenk I, et al. Changes in medication adherence among patients with asthma and COPD during the COVID-19 pandemic. *J Allergy Clin Immunol Pract* 2020; 8: 2384–2385.
- 36. De Boer GM, Houweling L, Hendriks RW, et al. Asthma patients experience increased symptoms of anxiety, depression and fear during the COVID-19 pandemic. *Chron Respir Dis* 2021; 18: 147997312110296.
- 37. Zein JG, Erzurum SC. Asthma is Different in Women. *Curr Allergy Asthma Rep* 2015; 15: 28.
- 38. Aydin H, Doğan H. COVID-19 outbreak impact on discharge against medical advice from the ED: A retrospective study. Am J Emerg Med 2022; 57: 21–26.
- 39. NYC Health. Disparities among Children with Asthma in New York City. Epi Data Brief. September 2021, No126. [Accessed on June 27, 2024]. Available from: https://www.nyc.gov/assets/doh/downloads/pdf/epi/databrief126.pdf.
- 40. Lau VI, Dhanoa S, Cheema H, et al. Non-COVID outcomes associated with the coronavirus disease-2019 (COVID-19) pandemic effects study (COPES): A systematic review and meta-analysis. *PLOS ONE* 2022; 17: e0269871.
- 41. Wichmann B, Moreira Wichmann R. Big data evidence of the impact of COVID-19 hospitalizations on mortality rates of non-COVID-19 critically ill patients. *Sci Rep* 2023; 13: 13613.
- 42. McAlister FA, Chu A, Qiu F, et al. Outcomes Among Patients Hospitalized With Non–COVID-19 Conditions Before and During the COVID-19 Pandemic in Alberta and Ontario, Canada. *JAMA Netw Open* 2023; 6: e2323035.
- 43. Skevaki C, Chinthrajah RS, Fomina D, et al. Comorbidity defines asthmatic patients' risk of COVID-19 hospitalization: A global perspective. *J Allergy Clin Immunol* 2023; 151: 110–117.
- 44. Tsukada A, Terada-Hirashima J, Takasaki J, et al. Clinical trends among patients with asthma hospitalized for COVID-19 based on data from a nationwide database: an observational study. *BMC Pulm Med* 2024; 24: 105.
- 45. Terry PD, Heidel RE, Dhand R. Asthma in Adult Patients with COVID-19. Prevalence and Risk of Severe Disease. *Am J Respir Crit Care Med* 2021; 203: 893–905.

Figure 1: Quarterly changes in healthcare utilization patterns and patient outcomes. A-Hospitalization cost. B- Asthma hospitalizations per 100,000 people. C- In-patient mortality rate per 100,000 people. D-Asthma hospitalizations per 100,000 people with LOS≥ 7 days.




Figure 2: Census division variation in the median cost of asthma hospitalization during the pandemic (2020) compared to pre-pandemic (2019 and 2018). The cost of asthma hospitalizations in every division significantly increased in 2020 compared to pre-pandemic (P < 0.05). The Pacific division had the highest hospitalization costs compared to other divisions each year (P < 0.05); There is also a significant increase in hospitalization cost in this division in 2020 compared to 2018 (p=0.005) but no significant increase between 2020 and 2019 (p>0.05).




Figure 3: Census division variation in the rate of asthma hospitalization per 100,000 during the pandemic (2020) compared to pre-pandemic (2019 and 2018). The rate of asthma hospitalizations in every division significantly decreased in 2020 compared to pre-pandemic (P < 0.0001). The Mid-Atlantic division had the highest hospitalization rates compared to other divisions each year (P < 0.001); there was also a significant decrease in hospitalizations in this division over the 3 years (p=0.01) and in 2020 compared to 2018 (p=0.04) and 2019 (p=0.04).




Figure 4: Census division variation in the in-patient asthma mortality rate per 100,000 during the pandemic (2020) compared to pre-pandemic (2019 and 2018). Compared to other divisions, the East North Central division had the highest mortality rate in 2018 (P < 0.05), while in 2019 the Mountain division had the highest mortality rate (P < 0.05). During the pandemic, the Mid-Atlantic division had the highest mortality rate compared to other divisions (P < 0.05).




Figure 5: Census division variation in the percentage of inpatient length of stay (LOS) longer than 7 days during the pandemic (2020) compared to pre-pandemic (2019 and 2018). Except for the Mid-Atlantic, East North Central, and Mountain divisions (p>0.05), the percentage of admissions with LOS> 7 days significantly decreased in all other divisions in 2020 compared to pre-pandemic (P < 0.05). The Mid-Atlantic division had

the highest rate of hospitalization with LOS>7 days compared to other divisions every year (P < 0.05).




Table 1. Patient and admission characteristics and outcomes stratified by years.

Year		Overall	2018	2019	2020	P-value
N (hospital admissions)		63,740	25,264	24,250	14,226	-
Weighted N		318,700	126,320	121,250	71,130	<0.0001
National Population in the US		986,517,534	326,686,501	328,329,953	331,501,080	-
Rate of Asthma Hospi 100,000	talizations per	32.3	38.6	37.0	21.4	<0.0001
		De	mographics		I	
Age (median [IQR])		38 [14,56]	36 [12,56]	38 [14,57]	41 [21,57]	<0.0001
	5-19 years	95,675	41,695 (33.0)	37,115 (30.6)	16,865 (23.7)	
A	20-44	90,890	34,100 (27.0)	34,035 (28.1)	22,755 (32.0)	0.0004
Age Group (%)	45-64	82,545	31,400 (24.8)	31,055 (25.6)	20,090 (28.2)	<0.0001
	65 and above	49,590	19,125 (15.1)	19,045 (15.7)	11,420 (16.1)	
Sex (Female (%))		202,880	79,735 (63.1)	77,300 (63.8)	45,845 (64.5)	<0.0001
	White	121,855	47,790 (38.9)	46,085 (38.8)	27,980 (40.2)	
	Black	107,490	41,860 (34.1)	41,255 (34.8)	24,375 (35.0)	<0.0001
Race (%)	Hispanic	58,115	23,430 (19.1)	22,560 (19.0)	12,125 (17.4)	
	Other	23,805	9,860 (8.0)	8,830 (7.4)	5,115 (7.4)	
		Socio-econ	omic Characteristi	cs	·	
	0-25 th percentile	117,975	46,730 (37.5)	44,775 (37.4)	26,470 (37.8)	
Median Household income (%)	26 th -50 th percentile	78,370	31,595 (25.3)	28,715 (24.0)	18,060 (25.8)	<0.0001
	51 st -75 th percentile	67,535	26,635 (21.4)	26,570 (22.2)	14,330 (20.5)	
	76 th -100 th percentile	50,455	19,735 (15.8)	19,580 (16.4)	11,140 (15.9)	
Urban-rural classes (%)	Metro counties > 1 million	127,590	50,785 (40.4)	48,465 (40.2)	28,340 (40.1)	
	Fringe counties of Metro area > 1 million	77,515	30,770 (24.5)	29,735 (24.6)	17,010 (24.1)	
	Counties Metro area of 250000- 999,000	58,685	23,295 (18.5)	22,300 (18.5)	13,090 (18.5)	<0.0001
	Counties in Metro areas 50,000- 249,999	22,645	8,845 (7.0)	8,450 (7.0)	5,350 (7.6)	
	Micropolitan areas	19,020	7,385 (5.9)	7,340 (6.1)	4,295 (6.1)	
	Rural areas	11,700	4,775 (3.8)	4,415 (3.7)	2,510 (3.6)	
	Medicaid	126,470	51,450 (41.63%)	47,505 (40.19%)	27,515 (39.70%)	
Primary payer (%)	Medicare	68,910	26,350 (21.32%)	26,475 (22.40%)	16,085 (23.21%)	<0.0001
Frinaly payer (%)	Private	<u>88 120</u>	35 345 (28 60%)	33 525 (28 36%)	10 250 (27 78%)	

	Self-Pay	25,735	9,690 (7.84%)	10,010 (8.47%)	6,035 (8.71%)	
	No Charge	1,865	760 (0.61%)	690 (0.58%)	415 (0.60%)	-
		Comorbidities				
Obesity (%)		82,710	30,880 (24.5)	31,675 (26.1)	20,155 (28.3)	<0.0001
Cardiovascular diseases (%)		45,485	17,225 (13.6)	17,120 (14.1)	11,140 (15.7)	<0.0001
Dyslipiden	nia (%)	54,195	20,245 (16.0)	20,745 (17.1)	13,205 (18.6)	<0.0001
Hypertensi	on (%)	113,520	43,000 (34.0)	43,065 (35.5)	27,455 (38.6)	<0.0001
Diabetes Me	llitus (%)	56,570	21,980 (17.4)	21,375 (17.6)	13,215 (18.6)	<0.0001
Chronic kidney o	diseases (%)	15,505	5,765 (4.6)	6,020 (5.0)	3,720 (5.2)	<0.0001
Cancer	(%)	3,085	1,085 (0.9)	1,120 (0.9)	880 (1.2)	<0.0001
Lung Cano	cer (%)	255	110 (0.09)	90 (0.07)	55 (0.08)	<0.0001
Allergy and Eczema (%)		32,400	13,395 (10.6)	12,420 (10.2)	6,585 (9.2)	<0.0001
Chronic sinusitis (%)		7,975	3,485 (2.8)	3,070 (2.5)	1,420 (2.0)	<0.0001
Sleep apnea (%)		44,435	16,810 (13.3)	17,410 (14.4)	10,215 (14.4)	<0.0001
GERD (%)		57,825	22,130 (17.5)	22,015 (18.2)	13,680 (19.2)	<0.0001
Depression (%)		32,930	12,340 (9.8)	12,605 (10.4)	7,985 (11.2)	<0.0001
Anxiety and related disorders (%)		50,865	18,825 (15.0)	19,005 (15.7)	13,035 (18.3)	<0.0001
Rheumatoid arthritis and other collagen diseases (%)		17,310	6,325 (5.0)	6,545 (5.4)	4,440 (6.2)	<0.0001
Liver diseases (%)		4,840	1,675 (1.3)	1,900 (1.6)	1,265 (1.8)	<0.0001
Substance a	buse (%)	24,940	9,000 (7.1)	9,010 (7.4)	6,930 (9.7)	<0.0001
		Characterist	ics of Hospitalizati	ons		
	January-March	100,370	36,165 (28.7)	33,260 (27.5)	30,945 (43.60)	<0.0001
Admission guarter	April-June	72,930	30,275 (24.0)	31,380 (25.9)	11,275 (15.88)	
(%)	July-September	61,735	24,920 (19.8)	24,460 (20.2)	12,355 (17.41)	
	October- December	82,995	34,710 (27.5)	31,880 (26.4)	16,405 (23.11)	
LOS in days median [IQR]		2 [1,3]	2 [1,3]	2 [1,3]	2 [1,4]	<0.0001
LOS >7 days		19,055	7,595 (6.0)	7,100 (6.0)	4,360 (6.1)	<0.0001
APRDRG-Asthma	Minor	121,590	45,495 (36.02)	50,535 (41.7)	25,560 (35.9)	<0.0001
severity (degree of loss of function)	Moderate	108,575	45,915 (36.35)	39,235 (32.4)	23,425 (32.9)	
	Major	73,230	27,630 (21.87)	26,885 (22.2)	18,715 (26.3)	
	Extreme	15,305	7,280 (5.76)	4,595 (3.8)	3,430 (4.8)	

APRDRG-Mortality likelihood	Minor	194,275	81,260 (64.33)	73,820 (60.88)	39,195 (55.10)	<0.0001
	Moderate	59,630	22,440 (17.76)	23,165 (19.11)	14,025 (19.72)	
	Major	57,070	20,175 (15.97)	21,365 (17.62)	15,530 (21.83)	
	Extreme	7,725	2,445 (1.94)	2,900 (2.39)	2,380 (3.35)	
In-patient mortality (%)		930	250 (0.20)	365 (0.30)	315 (0.44)	<0.0001
Total cost in USD median [IQR]		5,552 [3,635, 8,751]	5,251 [3,426, 8,278]	5,677 [3,725, 8,969]	5,881 [3,920, 9,216]	<0.0001
Disposition of patient (%)	Routine	284,410	113,265 (89.8)	108,480 (89.7)	62,665 (88.5)	
	Transfer to Short-term hospital	2,300	885 (0.7)	950 (0.8)	465 (0.7)	
	Transfer to other: SNF, ICF (%)	6,220	2,575 (2.0)	2,345 (1.9)	1,300 (1.8)	<0.0001
	Home Health Care (HHC)	15,425	6,080 (4.8)	5,710 (4.7)	3,635 (5.1)	
	Against Medical Advice (AMA)	9,415	3,265 (2.6)	3,400 (2.8)	2,750 (3.9)	

Table 2: Univariate and multivariable regression analysis of study outcomes, adjusted for demographics, comorbidities, and hospital admission characteristics.

	COVID-19) period	Pre-COVID-19 period			
	OR (95% CI)	aOR (95%)	OR (95% CI)	aOR (95%)		
In-patient mortality	1.79 (1.31-2.42)	1.27 (1.10-1.50)	0.56 (0.41-0.76)	0.78 (0.67-0.92)		
LOS≥7 days	1.03 (1.01-1.07)	0.95 (0.91-0.98)	0.97 (0.93-0.99)	1.05 (1.01-1.09)		
	Exponential of slope (95% CI)*	Adjusted Exponential of slope (95% Cl) [§]	Exponential of slope (95% CI)	Adjusted Exponential of slope (95% Cl)		
Cost	1.04 (1.03-1.05)	1.03 (1.03-1.04)	0.96 (0.95-0.97)	0.97 (0.96-0.97)		
LOS	1.01 (1.00-1.01)	0.99 (0.98-0.99)	0.99 (0.99-1.00)	1.01 (1.01-1.02)		
Percentage Change in cost= $\frac{e^{COVID-19} - e^{Pre-COVID-19period}}{e^{Pre-COVID-19period}} \times 100$						
*Unadjusted percent change =+8.3%						
§ adjusted percent change =+6.2%						